Description
Buy 2 Get 1 Free Blend CJC 1295 NO DAC 5MG with Ipamorelin 5MG :
| Unit Size | 10 mg/vial |
| Unit Quantity | 1 vial |
| Purity (Mass Spectrometry and UV) | 99.75% Nominal Target: 5 mg CJC 1295 NO DAC + 5 mg Ipamorelin |
| Sequence (CJC 1295 NO DAC) | H-Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu- Ser-Ala-Arg-Lys-Leu–Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2 |
| Sequence (IPAMORELIN) | Aib-His-D-2-Nal-D-Phe-Lys-NH2 |
| Molecular Formula (CJC 1295 NO DAC) |
C152H252N44O42 |
| Molecular Formula (IPAMORELIN) | C38H49N9O5 |
| Appearance | Lyophilized White Powder |
| Source | Chemical Synthesis |
| Storage | Lyophilized Blend CJC 1295 NO DAC with Ipamorelin is stable at roomTemperature for 90 days, however it is best to store in a freezer below – 8c for any extended period of time. |
| Terms | The products we offer are intended for laboratory research use only. Please familiarize yourself with our terms of service prior to ordering. |
Blend CJC-1295 NO-DAC 5mg with Ipamorelin 5mg
View Research Overview & References
This blend combines two synthetic peptides for use in in vitro and in vivo (animal) laboratory research on growth-related signaling. Both peptides are analogs of human growth hormone-releasing hormone (GHRH) and share the first 29 amino acids of the 44-amino-acid sequence found in GHRH.1,2
Animal Model Research
Animal studies have examined CJC-1295 and Ipamorelin’s effects on growth hormone (GH) release compared to control groups.2,3 CJC-1295 has been studied for its effects on insulin-like growth factor 1 (IGF-1) release in various animal models.4 Research on Ipamorelin has examined its role in bone formation markers. An 8-week study in rats demonstrated increases in bone mineral content following administration of Ipamorelin, GH, and related peptides, as measured by post-mortem bone scans.5
Peptide Stability Research
CJC-1295 is studied for its pharmacokinetic and pharmacodynamic properties relative to intrinsic GHRH. The modification of the amino acid sequence in CJC-1295 NO-DAC is associated with reduced degradation by peptidase enzymes, relevant to research on peptide stability.4
Combined Research Applications
The combination of CJC-1295 and Ipamorelin is studied for its effects on multiple signaling systems, including GH-related signaling, metabolic pathways, immune-related signaling, insulin regulation, and cell differentiation, making it a research tool for investigating growth-related and metabolic signaling in a controlled laboratory environment.
Important Notice
These peptides are synthesized, combined, and distributed strictly for in vitro and in vivo (animal) research purposes only. They are not intended for human or animal consumption, medical use, diagnostic use, or any application outside of laboratory research, and have not been evaluated for safety or efficacy in humans or animals.
Product Information
This combination is provided as a white lyophilized powder, with a concentration of 10 mg per vial (5 mg of each peptide).
References
1. Matsoukas MT, Spyroulias GA. Dynamic properties of the growth hormone-releasing hormone receptor (GHRHR) and molecular determinants of GHRH binding. Mol Biosyst. 2017;13(7):1313-1322.
2. Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 Nov;139(5):552-61.
3. Jetté L et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-8.
4. Campbell RM et al. Enhanced stability and potency of novel growth hormone-releasing factor (GRF) analogues derived from rodent and human GRF sequences. Peptides. 1994;15(3):489-95.
5. Svensson J et al. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. J Endocrinol. 2000 Jun;165(3):569-77.
